Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Gains from Sales and Divestitures (2016 - 2018)

Historic Gains from Sales and Divestitures for Teva Pharmaceutical Industries (TEVJF) over the last 10 years, with Q4 2018 value amounting to $1.6 million.

  • Teva Pharmaceutical Industries' Gains from Sales and Divestitures fell 1305.73% to $1.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.6 million, marking a year-over-year decrease of 1305.73%. This contributed to the annual value of $1.6 million for FY2018, which is 1305.73% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Gains from Sales and Divestitures of $1.6 million as of Q4 2018, which was down 1305.73% from $1.9 million recorded in Q4 2017.
  • In the past 5 years, Teva Pharmaceutical Industries' Gains from Sales and Divestitures registered a high of $1.9 million during Q4 2017, and its lowest value of -$1.1 million during Q4 2015.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $1.1 million (2014), whereas its average is $877200.0.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 19703.32% in 2015, then skyrocketed by 17464.03% in 2016.
  • Teva Pharmaceutical Industries' Gains from Sales and Divestitures (Quarter) stood at $1.1 million in 2014, then crashed by 197.03% to -$1.1 million in 2015, then surged by 174.64% to $830000.0 in 2016, then soared by 126.99% to $1.9 million in 2017, then decreased by 13.06% to $1.6 million in 2018.
  • Its Gains from Sales and Divestitures was $1.6 million in Q4 2018, compared to $1.9 million in Q4 2017 and $830000.0 in Q4 2016.